MOG and myeloid sarcoma: Clinical outcomes were more variable, with early predictors including sex (female sex linked to worse clinical outcomes in some cases), lesion location (brainstem and spinal lesions correlated with poorer outcomes), antibody status (MOG positivity favorable, AQP4 positivity unfavorable), diagnosis (MOGAD more favorable, MS and NMOSD less so), and DMT (generally associated with improved outcomes), but fewer consistent associations were observed beyond the first year.